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Abstract
Background: The emergence of multi-drug resistant Gram-negatives (MDRGNs) coupled with an alarming scarcity
of new antibiotics has forced the optimization of the therapeutic potential of available antibiotics. To exploit the
time above the minimum inhibitory concentration mechanism of β-lactams, prolonging their infusion may improve
outcomes. The primary objective of this meta-analysis was to determine if prolonged β-lactam infusion resulted in
decreased mortality and improved clinical cure compared to intermittent β-lactam infusion.
Methods: Relevant studies were identified from searches of MEDLINE, EMBASE, and CENTRAL. Heterogeneity was
assessed qualitatively, in addition to I
2 and Chi-square statistics. Pooled relative risks (RR) and 95% confidence
intervals (CI) were calculated using Mantel-Haenszel random-effects models.
Results: Fourteen randomized controlled trials (RCTs) were included. Prolonged infusion β-lactams were not
associated with decreased mortality (n= 982; RR 0.92; 95% CI:0.61-1.37) or clinical cure (n = 1380; RR 1.00 95%
CI:0.94-1.06) compared to intermittent infusions. Subgroup analysis for β-lactam subclasses and equivalent total
daily β-lactam doses yielded similar results. Most studies had notable methodological flaws.
Conclusions: No clinical advantage was observed for prolonged infusion β-lactams. The limited number of studies
with MDRGNs precluded evaluation of prolonged infusion of β-lactams for this subgroup. A large, multicenter RCT
with critically ill patients infected with MDRGNs is needed.
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Background
In the last several years, a progressive increase in resis-
tance among Gram-negative pathogens has continued
unabated. The emergence of multi-drug resistant Gram-
negative organisms (MDRGNs) coupled with an alarm-
ing scarcity of new antibiotic classes in the pipelines of
the pharmaceutical industry has forced the healthcare
community to optimize the therapeutic potential of cur-
rently available antibiotics [1].
The primary determinant of b-lactam efficacy is the
duration of time in which the non-protein bound
drugconcentration (fT) exceeds the minimum inhibitory
concentration (MIC) of the organism (fT>MIC) [2]. b-
lactam antibiotics have traditionally been administered
by intermittent infusion. With intermittent dosing, b-
lactams attain a high peak concentration, but short half-
lives can lead to precipitous drops in serum drug levels.
Optimizing fT>MIC is particularly difficult for organ-
isms with elevated MICs. Pharmacokinetic studies have
shown that prolonging the infusion time provides more
consistent serum levels and maximizes fT>MIC [3-7]. It
is unclear, however, if this translates to improved patient
outcomes.
Several trials comparing clinical outcomes of pro-
longed infusion b-lactams with standard dosing have
been completed, with conflicting results [7]. Moreover,
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as most trials were conducted with small numbers of
patients. We performed a systematic review and meta-
analysis of randomized controlled trials (RCTs) investi-
gating the efficacy of prolonged infusion b-lactam ther-
apy compared with intermittent infusion b-lactam
therapy with regards to mortality, clinical cure, and
adverse effects. The primary objective was to determine
if prolonged infusion of b-lactam antibiotics resulted in
improved patient survival and clinical cure compared to
intermittent dosing of b-lactam antibiotics. The second-
ary objective was to determine if prolonged infusion of
b-lactam antibiotics resulted in increased adverse effects
compared to standard, bolus dosing of b-lactam
antibiotics.
Methods
Definitions
Prolonged infusion of b-lactam antibiotics consisted of
either extended infusion or continuous infusion of the
antibiotic. Extended infusions were defined as intermit-
tent infusions lasting ≥ 3 hours, whereas continuous
infusion involved administration over a 24-hour period
at a fixed rate [8]. Intermittent infusion of b-lactam
antibiotics served as the control group and was defined
as standard infusions of antibiotics based on package
inserts. Identical b-lactams did not need to be adminis-
tered for both study arms in a particular trial, so long as
both drugs were b-lactam antibiotics with similar spec-
trums of activity.
Outcomes
The primary outcomes of thea n a l y s i sw e r em o r t a l i t y
and clinical cure. Mortality was assumed to be in-hospi-
tal mortality, a biologically relevant period in which
death can be considered a consequence of treatment
failure. Clinical cure was defined by the discretion of the
authors because of the heterogeneous nature of the
study population, pathogens involved, and the sites of
infections. The secondary outcome of the analysis was
adverse effects during b-lactam treatment.
Data sources
Relevant studies were identified from searches of MED-
LINE, EMBASE, and Cochrane Central Register of Con-
trolled Trials (CENTRAL) without imposing language or
study period restrictions. Databases were searched on
February 11, 2011 utilizing the final search strategy.
Appendix A contains the complete electronic search
strategy. Search terms for MEDLINE included descrip-
tors of population, drug, and administration schedule. A
similar method was employed to search EMBASE, with
different limits to capture clinical trials of humans and
to exclude review articles and case reports. Highly sensi-
tive RCT filters were incorporated for MEDLINE and
EMBASE searches. For CENTRAL a strategy similar to
that used for MEDLINE was utilized, without the highly
sensitive term for clinical trials. In addition, due to the
smaller size of the CENTRAL database, some terms in
the search strategy were altered to increase the sensitiv-
ity of the search. Two translators with a medical back-
ground were used for any non-English articles
encountered. After a final list of included articles was
compiled, Web of Science (accessed March 2
nd, 2011)
and a review of the citations for each article were con-
ducted to search for further potentially relevant articles
to include. First authors of studies needing further clari-
fication were contacted [5,9-12].
Study Selection
Two independent reviewers examined studies for inclu-
sion at both title/abstract and full-text review stages.
Any discrepancies between reviewers were resolved by
consensus of all study members. During initial title and
abstract selection, a broad criterion for inclusion was
encouraged and consisted of any study comparing pro-
longed infusion b-lactams to intermittent b-lactam infu-
sion in humans. Full text review was then conducted
with more conservative inclusion requirements. A study
was considered eligible if (1) it was an RCT, (2) it com-
pared prolonged infusion b-lactam antibiotics to inter-
mittent b-lactam antibiotics as treatment for
hospitalized patients with infections, and (3) it was con-
ducted in humans. Trials focusing on pharmacokinetic
or pharmacodynamic parameters with no description of
clinical outcomes were excluded. Cross-over RCTs were
excluded given concern that this intervention would
obscure the benefit of either method of b-lactam admin-
istration. Standardized data abstraction forms and risk of
bias forms were completed for all included studies.
Data extraction
Data were extracted by two independent reviewers. Any
disagreement was resolved by consensus with the
remaining reviewers. The following data were abstracted
from each study: study setting and time period, patient
ages, baseline APACHE II scores, body sites of infection,
and responsible pathogens. Antibiotic name, dose, inter-
val, and duration of infusion, as well as use of additional
antibiotics were also recorded. Definition of mortality,
clinical cure, adverse effects, and number of participants
discontinuing therapy were collected. Extracted data
were entered into RevMan version 5.0 software (Copen-
h a g e n :T h eN o r d i cC o c h r a n eC e n t r e ,T h eC o c h r a n e
Collaboration, 2008) and a second author independently
confirmed accurate data entry into this program.
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Two independent reviewers utilized guidelines from the
Cochrane Handbook for Systematic Reviews of Interven-
tions to assess manuscript quality [13]. Disagreements
were resolved by group consensus. Parameters evaluated
included sequence generation, allocation concealment,
masking, selective outcome reporting, differential loss to
follow-up, and intention-to-treat analysis. The source of
the study’sf u n d i n gw a sa l s od o c u m e n t e d .I fa n yo ft h i s
information could not be determined from study
description, “unclear” was documented.
Data analysis and statistical methods
Statistical analyses were performed using RevMan 5.0
software. After a qualitative assessment of heterogeneity,
quantitative heterogeneity was assessed by Chi
- square
statistics. The extent of the inconsistencies was charac-
terized using the I
2 statistic. Considerable heterogeneity
was indicated by I
2>50% [13]. All outcomes were
reported as dichotomous. Pooled relative risks (RR) and
95% confidence intervals (CI) for mortality and clinical
cure were calculated by use of the Mantel-Haenszel ran-
dom-effects model given the heterogeneity observed
between studies. Publication bias was assessed using
funnel plots on mortality and clinical cure endpoints.
Sensitivity analyses were performed to test our assump-
tion that inclusion of studies without strict intention-to-
treat analysis did not significantly alter results compared
to exclusion of these studies. Planned sub-group ana-
lyses included the following: continuous infusion b-lac-
tams (excluding extended infusion), b-lactam subclasses,
exclusion of pharmaceutical industry funded trials,
infections with MDRGNs, and restriction to studies with
equivalent total daily dose of b-lactams in both arms.
For all analyses, a p-value < 0.05 was regarded as statis-
tically significant.
Results
Study selection
We identified 3181 potentially relevant published arti-
cles on review of MEDLINE (n = 1884), EMBASE (n =
894), and CENTRAL (n = 403) (Figure 1). After remov-
ing 181 duplicates, 3000 titles and abstracts were
reviewed by two independent study team members.
Forty-four studies underwent full text review and 13
met criteria for inclusion. After review of Web of
Science and hand searching the citation list of each
included study, 1 additional study was included [14].
The baseline characteristics of the 14 included studies
are described in Table 1 [3,4,9,11,14-23].
Study characteristics
Study sample sizes varied from 10 to 531 patients. Stu-
dies were conducted on at least 4 continents, with the
majority in North America or Europe. Year of publica-
tion ranged from 1979 to 2008, with all but two studies
published after the year 2000 [15,19]. Patients were
admitted to the intensive care unit for all or part of
their admission in half of the included studies
[4,11,16,20,21].
Extended infusion b-lactams were administered in the
experimental arm in 3 studies, with the infusion time ran-
ging from 3-7 hours [14,18,21]. The remaining studies
included patients receiving continuous infusion b-lactams
[3,4,9,11,15-17,19,20,22,23]. Six studies used the same
total daily dose of b-lactams in both study arms
[9,15,17-20]. Table 2 describes the antibiotic dose and
infusion schedules in each study. In all studies utilizing a
continuous infusion mechanism of b-lactam delivery, a
loading dose of the b-lactam was initially administered
to ensure early attainment of fT>MIC. Patients received
additional non-b-lactam antibiotics in 11 studies
[4,9,11,14-17,19,21,22]. The medication in the study arms
differed in one trial in which doripenem was compared to
imipenem [21]. Because of the similar spectrum of activity
of these agents, this study was included. Duration of ther-
apy varied markedly between studies with a mean of 9.4
days. In several studies, b-lactam dosing was adjusted for
renal insufficiency [4,11,16,20,24].
Risk of bias within studies
In general, there were few methodologically sound stu-
dies with adequate sample sizes to definitively determine
whether prolonged infusion b-lactams are superior to
intermittent infusion b-lactams for the treatment of
infections in hospitalized patients. As outlined in Table
3, all included studies were RCTs but the method of
randomization was detailed in only three trials [9,11,15].
Inclusion and exclusion criteria were clearly defined in
all trials. All studies included participants ≥18 years of
age, although Angus et al and Hanes et al had younger
age limits of 14 years and 16 years, respectively [3,4].
Allocation concealment was implemented in only two
studies, as seen in Table 2[9,15]. The remaining studies
largely failed to address allocation concealment. Masking
was conducted in only one study [9]. Intention-to-treat
analysis was conducted in eight studies [9,15-19,21,22].
A sensitivity analysis was conducted including only
those studies that clearly indicated intention-to-treat
analysis to investigate the impact of decreasing metho-
dological quality among studies on our pooled RRs. The
quantitative summary measure of effect remained largely
unchanged, suggesting that our results were not dispro-
portionately influenced by inclusion of studies not utiliz-
ing intention-to-treat analyses (Table 4).
A pharmaceutical company was identified as the
source of funding for nine trials [3,11,14-16,19-21,23].
Funnel plots comparing prolonged infusion and
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screen for evidence of publication bias for the mortality
and clinical cure outcomes (Figure 2). For the mortality
outcome, the plot suggested a paucity of studies indicat-
ing a protective effect of prolonged b-lactam infusion of
mortality. A funnel plot evaluating the outcome of clini-
cal cure, however, was relatively symmetrical, suggesting
minimal publication bias. Overall, based on qualitative
a n dq u a n t i t a t i v ee x p l o r a t i o n ,n oc o n c l u s i v ee v i d e n c eo f
reporting bias was found.
Mortality
Eight studies reported mortality as an outcome (Figure 3).
Among the 487 patients enrolled in the prolonged infusion
b-lactam arm, there were 53 deaths, compared to 56
deaths among the 495 patients in the intermittent infusion
arm. These differences were not statistically significant
with an RR of 0.92 (95% CI 0.61 - 1.37). The overall I
2 sta-
tistic was 9% suggesting relatively low heterogeneity
between the studies. Similarly, the Chi-square statistic was
7.66, p = 0.36. All studies except one crossed the null
value [4]. Mortality ranged from 2% in a trial consisting of
a relatively young population with low severity of illness to
57% in a severely ill population infected with a highly
pathogenic organism, Burkholderia pseudomallei [4,20].
Only one study demonstrated a mortality advantage to
prolonged infusion b-lactams [4]. This was the only study
in which all included subjects were in critical condition
and had bacterial cultures confirming infection with a
resistant Gram-negative organism.
Because of an ap r i o r ihypothesis that certain b-lac-
tams may be more effective with prolonged infusion
mechanisms than others, subgroup analysis of each of
the b-lactam subclasses was conducted. This hypothesis
was based on the observation that some b-lactams, like
piperacillin, have a MIC breakpoint higher than postu-
lated to be effective based on Monte Carlo simulation
techniques [8]. No significant differences were found
between subclasses, although each of these subgroups
was relatively small. Similarly, subgroup analyses includ-
ing only studies that used continuous infusion b-lac-
tams, only non-pharmaceutical industry sponsored trials,
and only studies utilizing equivalent total daily b-lactam
dose in both study arms did not yield results different
from the pooled RR derived from inclusion of all studies
(Table 4). A subgroup analysis was planned for studies
with highly resistant organisms, but the MIC for organ-
isms was not reported in the vast majority of trials, pre-
cluding completion of this subgroup analysis.
Clinical cure
All but one study included clinical cure as an outcome
(Figure 4) [4]. Proportion of clinical cure ranged from
32% to 100%. In the prolonged arm, 470 out of 677
Figure 1 Flow diagram of selection of articles for inclusion in meta-analysis of randomized controlled trials comparing clinical
outcomes of prolonged infusion and intermittent infusion of b-lactams in hospitalized inpatients.
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This compared to 479 out of 703 in the standard infu-
sion arm. The pooled RR was 1.00 (95% CI 0.94-1.06).
The I
2 statistic was 0%, and similarly the Chi-square sta-
tistic did not indicate heterogeneity (p = 0.58). Similar
to mortality, no significant difference was observed in
clinical success between prolonged infusion and inter-
mittent infusion b-lactam antibiotics. Only one study
demonstrated a statistically significant clinical cure out-
come, favoring the prolonged infusion arm [9]. Of
importance, this was the only study in which the alloca-
tion sequence was adequately generated, allocation con-
cealment was appropriate, some degree of blinding
occurred, and appropriate intention to treat analysis was
utilized. Subgroups for clinical cure were analyzed in
the same manner as mortality, with results that were
similar to pooled estimates as displayed in Table 4.
Adverse effects
Six studies reported adverse effects during administration
of the study medication. The most common reported
adverse effects were diarrhea and hepatotoxicity. For
almost all studies, the inclusion criteria for adverse effects
were not developed ap r i o r i .T h ed e f i n i t i o no fa d v e r s e
effects varied substantially between studies preventing
calculation of a meaningful pooled RR ratio (Figure 5).
Study withdrawals
Differential losses to follow-up appeared to be minimal,
as rates of study withdrawals were relatively similar
Table 1 Characteristics of eligible studies included in a meta-analysis of prolonged infusion versus intermittent
infusion of b-lactams in hospitalized patients
Study Country Setting Sample
Size
Type of Infection Mean Age
(range)
Mean
APACHE II
Score
(range)
Definition of Clinical Cure
Angus
2000
Thailand Not
specified
21 Septicemia,
meliodosis
NA (27-73) NA (3-27) Not specified
Bodey
1979
USA Non-ICU 204 Bacteremia,
pneumonia, UTI†,
neutropenic Fever
Not
specified
Not
specified
Disappearance of all clinical and laboratory evidence
of infection at the time administration of antibiotics
was discontinued
Buck 2005 Germany Non-ICU 24 Various 60.3 (32-88) Not
specified
Improvement of clinical and laboratory signs of
infection: resolution of fever, decreased CRP,
normalized leukocytes, CXR resolution
Georges
2005
France ICU 50 Pneumonia,
bacteremia
48.0 Not
specified
Complete resolution of infectious signs without
further need for antibiotics
Hanes
2000
USA ICU 32 Pneumonia 34.5 11.6 Complete resolution of all signs/symptoms of
pneumonia, or improvement in 1+ signs/symptoms
of pneumonia
Kojika
2005
Japan Not
specified
10 Abdominal
abscesses
63.7 (43-85) 12.5 (9-21) Afebrile and normalized white blood cell count
Lagast
1983
Belgium Not
specified
45 Septicemia Not
specified
Not
specified
Disappearance of all clinical and laboratory evidence
of infection
Lau 2006 USA ICU 262 Abdominal
infections
49.8 (18-95) 7.9 (0-31) Complete resolution of clinical signs and symptoms
or improvement (reduction of majority of signs and
symptoms and no new signs of infection)
Lubasch
2003
Germany Not
specified
81 COPD††
exacerbations
65.3 Not
specified
Recurrence to situation before exacerbation
Merchant
2008
USA,
Europe
ICU 531 Pneumonia 51.5 NA (8-29) Microbiologic and clinical response
Nicolau
2001
USA ICU 41 Pneumonia,
bacteremia
51.1 14.7 Complete resolution of pneumonia or lack of
progression of abnormalities on chest radiograph
Rafati
2006
Iran ICU 40 Pneumonia,
bacteremia, UTIs,
SSI, abdominal
infections
49 15.3 Change in APACHE II score, afebrile, normalization of
WBC
Roberts
2007
Australia ICU 57 Septicemia 47.4 17.6 Disappearance of all signs and symptoms related to
the infection
Van
Zanten
2006
Netherlan
ds
Not
specified
93 COPD
exacerbations
66.0 (34-76) Not
specified
Infiltrate improvement on x-ray, clinical improvement,
and no need for antibiotic treatment within 48 h
after cefotaxime discontinuation
†Urinary tract infection; ††chronic obstructive pulmonary disease.
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Page 6 of 13between study arms (Figure 6). No study reported
greater than 12% study withdrawal. [3,4,9,16-22,24]
Because of the scarcity of details regarding reasons for
withdrawals, a summary statistic for withdrawals was
not calculated.
Discussion
Several observational studies with varying study designs
comparing clinical benefits of prolonged and intermit-
tent infusion of b-lactam antibiotics have been con-
ducted with inconsistent results. A prospective study of
Table 3 Risk of bias assessment of eligible studies included in a meta-analysis of prolonged infusion versus
intermittent infusion of b-lactams in hospitalized patients
Study Funding Source Allocation Sequence
Adequately Generated
Allocation
Concealment
Masking Similar Rates of
Withdrawals Between
Groups
Intention to
Treat Analysis
Angus
2000
Wellcome Trust of Great
Britain
Unclear Unclear Unclear Yes No
Bodey
1979
Pharmaceutical company Yes Yes Unclear Unclear Yes
Buck 2005 Pharmaceutical company Unclear Unclear No Yes Yes
Georges
2005
Not specified Unclear Unclear No Yes Yes
Hanes
2000
Pharmaceutical company Unclear Unclear Unclear Yes No
Kojika
2005
Not specified Unclear No No Yes Yes
Lagast
1983
Pharmaceutical company Unclear Unclear Unclear Yes Yes
Lau 2006 Pharmaceutical company Unclear Unclear No Yes No
Lubasch
2003
Pharmaceutical company Unclear Unclear No Unclear Unclear
Merchant
2008
Pharmaceutical company Unclear Unclear No Yes Yes
Nicolau
2001
Pharmaceutical company Yes Unclear No Yes No
Rafati
2006
Tehran University Medical
Sciences Research Board
Unclear Unclear No Yes Yes
Roberts
2007
National Health & Medical
Research Council
Yes Yes Yes
a Yes Yes
Van
Zanten
2006
Pharmaceutical company Unclear Unclear No No No
aOnly outcome assessors were masked.
Table 4 Summary of subgroup and sensitivity analysis of eligible studies included in a meta-analysis of prolonged
infusion versus intermittent infusion of b-lactams in hospitalized patients†
Sub-group analysis Studies
Included
Mortality
Risk Ratio (95%
CI)
I
2 % Studies
Included
Clinical Cure
Risk Ratio (95%
CI)
I
2%
b-lactam subclasses
Penicillins 2 0.62 (0.19-2.03) 0 3 0.77 (0.46-1.30) 0
Cephalosporins 4 0.95 (0.35-2.63) 50 8 1.04 (0.92-1.18) 35
Carbapenems 2 1.08 (0.64-1.82) 0 2 1.00 (0.69-1.44) 0
Continuous infusion 6 0.80 (0.42-1.50) 22 10 1.01 (0.92-1.10) 16
Not funded by pharmaceutical industry 5 0.80 (0.37-1.73) 26 5 1.15 (0.85-1.57) 57
Equivalent daily dose of b-lactam antibiotic 5 1.30 (0.59-2.87) 0 6 1.06 (0.90-1.25) 48
Sensitivity-analysis
Intention-to-treat analysis 8 1.10 (0.75-1.60) 0 8 1.05 (0.93-1.19) 21
† Reference group is intermittent b-lactam infusion.
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Page 7 of 1398 hospitalized patients who were prescribed piperacil-
lin-tazobactam revealed a trend towards greater clinical
success in the continuous infusion group when com-
pared with intermittent infusion recipients [25]. In a ret-
rospective cohort study of piperacillin-tazobactam for
Pseudomonas aeruginosa sepsis, a significantly lower 14-
day mortality rate and shorter hospital length of stay in
patients receiving extended infusion, was demonstrated
[26]. Results from another retrospective cohort study
showed increased clinical cure by continuous versus
intermittent infusion of piperacillin-tazobactam in adults
with ventilator-associated pneumonia (VAP) caused by
Gram-negative pathogens with MICs ≥8 μg/ml [27]. A
third retrospective cohort study, however, failed to
demonstrate improved clinical outcomes with extended
infusion piperacillin-tazobactam [28]. Drug-related
adverse effects were mild and reported in similar num-
bers in both treatment arms in all of these studies
[25-28]. Retrospective studies comparing continuous
infusion versus intermittent infusion cefepime and mer-
openem in patients with VAP both noted significantly
improved clinical cure rates in the continuous infusion
arms [29,30].
In an attempt to clarify the comparative effect of pro-
longed versus intermittent infusion b-lactam antibiotics
on mortality, clinical cure, and adverse effects, we ana-
lyzed RCTs that offered the most methodologically rig-
orous evidence from the available studies. Our results
do not demonstrate a clinical advantage to prolonged
infusion b-lactams for routine use in hospitalized
patients. Sensitivity analyses and various sub-group ana-
lyses determined by ap r i o r ibiologically-plausible
hypotheses similarly did not indicate an advantage to
prolonged infusion b-lactams.
Two previous systematic reviews and meta-analyses
were published to answer similar questions [31,32]. A
Figure 2 Funnel plots demonstrating the possibility of a small publication bias assessing studies reporting mortality (left) but low
probability of publication bias assessing studies reporting clinical cure (right) comparing prolonged and intermittent infusion of b-
lactam antibiotics in hospitalized patients.
Figure 3 Mortality comparing prolonged infusion and intermittent infusion of b-lactam antibiotics in hospitalized patients.
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Page 8 of 13previous meta-analysis included continuous infusion of
aminoglycosides and vancomycin, making it difficult to
isolate the benefit of b-lactams [32]. A prior systematic
review focused on continuous infusion b-lactams in the
p r o l o n g e da r ma n di n c l u d e dc r o s s - o v e rs t u d i e s[ 3 1 ] .In
vitro evidence demonstrates similar properties of
fT>MIC for both extended and continuous infusion b-
lactams making their effect likely comparable, thus we
elected to include both groups under the umbrella term
“prolonged infusion,” a decision that was further sup-
ported by our sub-group analysis of only studies exam-
ining continuous b-lactam infusions. Inclusion of cross-
over studies obscures clinical benefits attributable to the
different infusion schedules, and therefore these studies
were excluded in the present review. The current meta-
analysis includes two additional RCTs, consisting of 612
patients, compared with those published previously
[14,21]. Overall, the findings of our meta-analysis are
consistent with those previously described [31,32].
Our study has several limitations that should be taken
into account when interpreting the results. Overall, the
included studies were of moderate to poor quality with
regards to answering our clinical question of interest
and had notable methodological differences. Allocation
sequence generation and allocation concealment were
not addressed in most studies. As a result, most of these
studies were at risk for selection bias. Similarly, most of
the studies did not adequately address masking, making
detection bias a consideration. Although masking of
health care providers and patients may be difficult to
impose because of the nature of the intervention, mask-
ing of outcome assessors would certainly be reasonable.
Of interest, the study with the most stringent methods
was the only one to show a clinical cure advantage for
prolonging b-lactam infusions [9]. Most trials were
funded by the pharmaceutical industry, making report-
ing bias a concern. Studies conducted by the pharma-
ceutical industry with unfavorable results for prolonged
infusion b- l a c t a m sm a yb el e s sl i k e l yt ob ep u b l i s h e d
[33].
Another noteworthy limitation is that participants in
the available studies were frequently receiving additional
antibiotics, generally aminoglycosides, limiting conclu-
sions about the sole contribution of the b-lactam anti-
biotics. In reality, however, when prolonged b-lactams
are administered, it is generally a final attempt to rid
the body of a particular pathogen and is administered in
conjunction with aminoglycoside therapy, making the
design of several of these studies similar to actual clini-
cal practice [7]. Only six of the studies used the same
total daily dose of b-lactam antibiotic in both arms
[8,9,15,17-19]. The majority of studies used a higher
dose of antibiotic in the intermittent infusion arm and
this unequal treatment favoring standard infusions could
have biased the results towards the null. Subgroup ana-
lysis of studies with equivalent total daily dose of b-
Figure 4 Clinical cure comparing prolonged infusion and intermittent infusion of b-lactam antibiotics in hospitalized patients.
Figure 5 Adverse effects comparing prolonged and intermittent infusion of b-lactam antibiotics in hospitalized patients.
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Page 9 of 13lactam antibiotic in both arms was conducted and did
not demonstrate any significant results; however, inter-
pretation of these results is limited by the relatively
small sample size of this population and the notable het-
erogeneity of these trials (I
2 =50%).
Perhaps the biggest limitation to our study is that the
bacterial isolates identified in the included RCTs gener-
ally had MICs in the susceptible range. Little difference
exists between intermittent and prolonged administra-
tion of b-lactams in achieving fT>MIC in this range of
susceptibility [2]. However, when less susceptible organ-
isms are present, the likelihood for treatment failure
increases with intermittent dosing. In one study, main-
taining a fT>MIC of 100% for cephalosporins was asso-
ciated with significantly improved clinical cure
compared to maintenance of fT>MIC at lower percen-
tages [34]. Prolonged infusion therapy is generally con-
sidered in clinical scenarios involving MDRGN
organisms with elevated MICs. From the available
R C T s ,i tc a n n o tb ed e t e r m i n e di fp r o l o n g e di n f u s i o nb-
lactams result in greater clinical success than standard
b-lactam infusions when MDRGNs are the offending
pathogens. Interestingly, the one study conducted in cri-
tically ill patients with microbiological evidence of a
resistant Gram-negative organism did in fact show a
mortality benefit in favor of prolonged b-lactam admin-
istration [4]. Perhaps, inclusion of studies with a low
burden of disease and highly susceptible microorganisms
in our review may have diluted the true effect of pro-
longed antibiotic infusion regimens.
Despite these limitations, this systematic review and
meta-analysis add useful information to the literature. The
14 included studies span 4 continents and are not
restricted to the English language, thus increasing general-
izability. As only RCTs were included, baseline characteris-
tics including age, severity of illness, body site of infection,
responsible pathogens, and underlying medical conditions
were similar between the treatment groups. Confounding
by indication can be extremely problematic in observa-
tional studies, as prognostic factors may influence treat-
ment decisions. However, this was unlikely in the included
trials because of the process of randomization.
Optimizing the pharmacokinetics-pharmacodynamics
of currently available antibiotics is necessary in the era
of MDRGN infections. Known b-lactam pharmacody-
namics support the concept of prolonged infusion to
maximize fT>MIC, but limited clinical data exist regard-
ing the comparative efficacy of prolonged b-lactam infu-
sion. The results of this meta-analysis do not support an
advantage to the use of prolonged infusion b-lactam
antibiotics as standard practice for hospitalized patients.
These findings remained consistent in the multiple sen-
sitivity and subgroup analyses that were evaluated.
Conclusions
Prolonged infusion b-lactam antibiotics may have value
in a specific subsets of patients, such as those with
highly-resistant Gram-negative infections because of
exploitation of their property of fT>MIC. Unfortunately,
the very limited number of patients in the included
RCTs with MDRGNs precluded evaluation of this sub-
group in the present meta-analysis. Methodologically
rigorous studies analyzing prolonged infusion b-lactams
for critically ill patients with MDRGN infections are
necessary to substantiate this potential benefit.
Endnotes
APPENDIX: Final Electronic Search Strategy (February 11,
2011)
MEDLINE Search Strategy
(("beta-lactams"[MeSH] OR “beta-lactams"[tiab] OR “beta
lactam"[tiab]) AND ("anti-bacterial agents"[MeSH] OR
("anti-bacterial"[tiab] AND “agents"[tiab]) OR “anti-bac-
terial agents"[tiab] OR “antibiotics"[tiab] OR “antibiotic"[-
tiab]) OR “beta-lactam antibiotics"[tiab] OR “beta-lactam
antibiotic"[tiab] OR doripenem[Title/Abstract] OR cefe-
pime[Title/Abstract] OR ceftazidime[Title/Abstract] OR
piperacillin[Title/Abstract] OR piperacillin/tazobactam
[tiab] OR piperacillin-tazobactam[tiab] OR cefamandole
[tiab] OR cefazolin[tiab] OR cefotaxime[tiab] OR cef-
triaxone[tiab] OR imipenem[tiab] OR meropenem[tiab]
OR ertapenem[tiab] OR cefoperazone[tiab] OR penicillin
[tiab] OR penicillins[tiab] OR imipenem-cilastatin[tiab]
OR ampicillin[tiab] OR ampicillin-sulbactam[tiab] OR
Figure 6 Study participant withdrawals comparing prolonged and intermittent infusion of b-lactam antibiotics in hospitalized
patients.
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Page 10 of 13sulbactam-ampicillin[tiab] OR tazocin[tiab] OR carbeni-
cillin[tiab] OR carbapenem[tiab] OR cephalosporin[tiab]
OR cephalosporins[tiab] OR ticarcillin-clavulanate[tiab]
OR cefpirome[tiab] OR flucloxacillin[tiab] OR mezlocil-
lin[tiab] OR aztreonam[tiab] OR cefuroxime[tiab] OR
ceftizoxime[tiab])
AND
("Drug Administration Schedule"[Mesh] OR “Infu-
sions, Intravenous"[MeSH] OR “continuous infusion"[Ti-
tle/Abstract] OR “extended infusion"[Title/Abstract] OR
“intermittent therapy"[Title/Abstract] OR ((continuous
[tiab] OR bolus[tiab] OR extended[tiab] OR intermittent
[tiab]) AND (administration[tiab] OR infusion[tiab] OR
dosing[tiab])))
AND
("hospitalized"[tiab] OR “hospitalised"[tiab] OR “hospi-
talization"[tiab] OR “hospitalisation"[tiab] OR “Bacterial
Infections"[Mesh] OR “sepsis"[Title/Abstract] OR
(("intensive"[tiab] OR “critical"[tiab] OR “acute"[tiab])
AND ("care"[tiab] OR “unit"[tiab] OR “illness"[tiab])))
AND
(randomized controlled trial[pt] OR controlled clinical
trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug
therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups
[tiab] NOT (animals[mh] NOT humans[mh]))
Cochrane Search Strategy
(("beta-lactams"[MeSH] OR “beta-lactams"[all fields] OR
“beta lactam"[all fields]) AND ("anti-bacterial agents"[-
MeSH] OR ("anti-bacterial"[all fields] AND “agents"[all
fields]) OR “anti-bacterial agents"[all fields] OR “antibio-
tics"[all fields] OR “antibiotic"[all fields]) OR “beta-lactam
antibiotics"[tiab] OR “beta-lactam antibiotic"[tiab] OR
doripenem[Title/Abstract] OR cefepime[Title/Abstract]
OR ceftazidime[Title/Abstract] OR piperacillin[Title/
Abstract] OR piperacillin/tazobactam[tiab] OR piperacil-
lin-tazobactam[tiab] OR cefamandole[tiab] OR cefazolin
[tiab] OR cefotaxime[tiab] OR ceftriaxone[tiab] OR imi-
penem[tiab] OR meropenem[tiab] OR ertapenem[tiab]
OR cefoperazone[tiab] OR penicillin[tiab] OR penicillins
[tiab] OR imipenem-cilastatin[tiab] OR ampicillin[tiab]
OR ampicillin-sulbactam[tiab] OR sulbactam-ampicillin
[tiab] OR tazocin[tiab] OR carbenicillin[tiab] OR carba-
penem[tiab] OR cephalosporin[tiab] OR cephalosporins
[tiab] OR ticarcillin-clavulanate[tiab] OR cefpirome[tiab]
OR flucloxacillin[tiab] OR mezlocillin[tiab] OR aztreo-
nam[tiab] OR cefuroxime[tiab] OR ceftizoxime[tiab])
AND
("Drug Administration Schedule"[Mesh] OR “Infu-
sions, Intravenous"[MeSH] OR “continuous infusion"[Ti-
tle/Abstract] OR “extended infusion"[Title/Abstract] OR
“intermittent therapy"[Title/Abstract] OR ((continuous
[tiab] OR bolus[tiab] OR extended[tiab] OR intermittent
[tiab]) AND (administration[tiab] OR infusion[tiab] OR
dosing[tiab])))
AND
("inpatient"[mesh] OR “hospitalized"[tiab] OR “hospi-
talised"[tiab] OR “hospitalization"[tiab] OR “hospitalisa-
tion"[tiab] OR “Bacterial Infections"[Mesh] OR
“sepsis"[Title/Abstract] OR (("intensive"[tiab] OR “criti-
cal"[tiab] OR “acute"[tiab]) AND ("care"[tiab] OR “uni-
t"[tiab] OR “illness"[tiab])))
EMBASE Search Strategy
(’hospital patients’:ab,ti OR ‘hospitalized patients’:ab,ti
OR ‘hospitalised patients’:ab,ti OR ‘hospital infection’/
exp OR (’sepsis’:ab,ti) OR (’septicemia’:ab,ti) OR (’septic
shock’:ab,ti) OR (’bacterial infection’/exp) OR (’critically
ill patient’:ab,ti) OR (’critically ill patients’:ab,ti) OR (’cri-
tical illness’:ab,ti) OR (’systemic inflammatory response
syndrome’:ab,ti))
AND
((’beta lactams’/exp) OR ‘doripenem’:ab,ti OR ‘cefepime’:
ab,ti OR ‘ceftazidime’:ab,ti OR ‘piperacillin’:ab,ti OR ‘piper-
acillin tazobactam’:ab,ti OR ‘piperacillin’:ab,ti OR ‘pipera-
cillin tazobactam combination product’:ab,ti OR
‘tazobactam’:ab,ti OR ‘cefamandole’:ab,ti OR ‘cefazolin’:ab,
ti OR ‘cefotaxime’:ab,ti OR ‘ceftriaxone’:ab,ti OR ‘imipe-
nem’:ab,ti OR ‘meropenem’:ab,ti OR ‘ertapenem’:ab,ti OR
‘cefoperazone’:ab,ti OR ‘penicillin’:ab,ti OR ‘penicillins’:ab,
ti OR ‘imipenem-cilastatin’:ab,ti OR ‘ampicillin’:ab,ti OR
‘ampicillin-sulbactam’:ab,ti OR ‘sulbactam-ampicillin’:ab,ti
OR ‘tazocin’:ab,ti OR ‘carbenicillin’:ab,ti OR ‘carbapenem’:
ab,ti OR ‘cephalosporin’:ab,ti OR ‘cephalosporins’:ab,ti OR
‘ticarcillin-clavulanate’:ab,ti OR ‘cefpirome’:ab,ti OR ‘flu-
cloxacillin’:ab,ti OR ‘mezlocillin’:ab,ti OR ‘aztreonam’:ab,ti
OR ‘cefuroxime’:ab,ti OR ‘ceftizoxime’:ab,ti)
AND
(’drug administration’/exp OR ‘intravenous drug
administration’/exp OR ‘drug intermittent therapy’/exp
OR (’continuous infusion’:ab,ti) OR (’extended infusion’:
ab,ti) OR ‘intermittent therapy’:ab,ti OR ((’continuous’:
ab,ti OR ‘bolus’:ab,ti OR ‘extended’:ab,ti OR ‘intermit-
tent’:ab,ti) AND (’administration’:ab,ti OR ‘infusion’:ab,ti
OR ‘dosing’:ab,ti)))
AND
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Page 11 of 13(((’randomized controlled trial’/exp OR ‘clinical trial’/
exp) OR (’randomization’/exp)))
AND
[humans]/lim
AND
NOT (’review’/exp OR review)
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